Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)

Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)

The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading drugs worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its cost, ICI is marked as a paradigm shift, offering the potential of a long-term cure. To reduce cos...

Full description

Bibliographic Details
Main Authors: Jia Li Low, Yiqing Huang, Kenneth Sooi, Zhi Yao Chan, Wei Peng Yong, Soo Chin Lee, Boon Cher Goh
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
PDL1
attenuated
lung cancer
immunotherapy
immune check inhibitor (ICI)
dose
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.932212/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.932212/full

Similar Items